Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Daisuke KobayashiYoshinari MochizukiKoji ToriiShin TakedaYoshihisa KawaseKiyoshi IshigureHitoshi TeramotoMasahiko AndoYasuhiro KoderaPublished in: International journal of clinical oncology (2020)
The modified dose reduction criteria for triweekly administration of nab-paclitaxel resulted in decreased incidence of severe peripheral sensory neuropathy without decline in efficacy.
Keyphrases
- phase ii
- clinical trial
- chemotherapy induced
- open label
- phase iii
- advanced non small cell lung cancer
- placebo controlled
- double blind
- neoadjuvant chemotherapy
- risk factors
- locally advanced
- study protocol
- early onset
- squamous cell carcinoma
- randomized controlled trial
- lymph node
- drug induced
- epidermal growth factor receptor